Business Context and Reporting Period
This Form 8-K reports on the 2025 Annual Meeting of Stockholders held by Immunome, Inc. on June 10, 2025. The company is an emerging growth company incorporated in Delaware, with its principal executive offices in Bothell, Washington. As of the record date of April 21, 2025, there were 87,011,822 shares of common stock outstanding and entitled to vote.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters and voting results rather than financial performance.
Material Changes and Voting Results
Proposal 1: Election of Directors
Stockholders elected two Class II Directors to serve until the 2028 Annual Meeting. The voting results were as follows:
- Isaac Barchas: 46,329,807 votes For; 15,249,792 votes Withheld; 14,740,497 Broker Non-Votes.
- Jean-Jacques Bienaimé: 47,144,944 votes For; 14,434,655 votes Withheld; 14,740,497 Broker Non-Votes.
Proposal 2: Ratification of Independent Auditor
Stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025. The voting results were as follows:
- Votes For: 76,259,572
- Votes Against: 15,957
- Abstentions: 44,567
- Broker Non-Votes: 0
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the disclosure of voting outcomes.
Key Facts for Investor Verification
- Confirmation that Isaac Barchas and Jean-Jacques Bienaimé were successfully elected as Class II Directors.
- Verification that Ernst & Young LLP was ratified as the auditor for the fiscal year ending December 31, 2025.
- Review of the significant number of broker non-votes (14,740,497) recorded for the director elections.
- Confirmation of the total shares outstanding (87,011,822) as of the April 21, 2025 record date.